Introduction {#Sec1}
============

The increased incidence of chronic kidney disease (CKD) over the last decades is related to the aging population and to lifestyle-related diseases, e.g., hypertension, atherosclerosis and diabetes. For patients progressing to end-stage renal disease, renal replacement therapy is the final treatment option. When compared to the general population, patients receiving renal replacement therapy are at increased risk of infections, malignancies and cardiovascular events (Vogelzang et al. [@CR33]). In renal transplant recipients (RTR), one of the main pathophysiological processes that contribute to premature cardiovascular disease is endothelial dysfunction. Different processes including decreased expression of glomerular endothelial nitric oxide synthase (eNOS) expression after renal transplantation (Albrecht et al. [@CR2]) are thought to play a role in these adverse events. The subsequent reduction in NO release may cause vascular damage through changes in the renal hemodynamics (Nakayama et al. [@CR24]) and enhanced endothelial adhesion of leukocytes and platelets (Huang et al. [@CR16]).

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide (NO) synthase and thereby considered an adverse mediator of endothelial function (Cooke [@CR6]; Yilmaz et al. [@CR34]). ADMA is associated with cardiovascular risk factors in patients with hypertension (Surdacki et al. [@CR27]), diabetes (Can et al. [@CR5]) and hyperlipidemia (Boger et al. [@CR4]). This is further evidenced by increased plasma levels of ADMA in patients with CKD, which are linked to both the development and the progression of CKD (Ravani et al. [@CR25]; Fliser et al. [@CR12]; Hanai et al. [@CR14]). In pre-dialysis patients with CKD, circulating levels of ADMA are an independent risk factor for left ventricular hypertrophy with predictive value for cardiovascular events (Shi et al. [@CR26]). Interestingly, a recent study in patients with CKD demonstrated a link between levels of ADMA and fibroblast growth factor-23 (FGF-23), which by itself is also linked to markers of endothelial cell injury (Malyszko et al. [@CR21]), in the development of endothelial dysfunction (Yilmaz et al. [@CR35]). Furthermore, a recent study in CKD patients suggested that the association between ADMA level and CKD progression is modified by FGF23 (Tripepi et al. [@CR28]). Whether this effect modification also occurs in renal transplant recipients for graft and patient survival, or whether the association between ADMA and these outcomes is mediated by FGF-23 is unknown.

Based on the characteristics of ADMA, especially those related to endothelial dysfunction, we hypothesized that ADMA is associated with graft failure and mortality after kidney transplantation. We investigated this in a cohort of 686 renal transplant recipients with long-term follow-up.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

From November 2008 till June 2011, all stable RTR (≥18 years, *n* = 817) with a functioning graft for over 1 year that visited the outpatient clinic of the University Medical Center Groningen (UMCG), the Netherlands were invited to participate. After giving written informed consent, a total of 707 (87 %) RTR participated in the present study. Plasma ADMA was measured in samples of 686 RTR (97 %). Further details of the study population have been published previously (van den Berg et al. [@CR30], [@CR31], [@CR32]). The study protocol was approved by the Review Board of the UMCG (METc 2008/186) and was in adherence to the Declaration of Helsinki.

Outcome parameters {#Sec4}
------------------

The primary outcome measures of this study were death-censored graft failure (defined as restart of dialysis or re-transplantation) and all-cause mortality. Outcome measures were recorded until the end of May 2013, with no participants lost to follow-up.

Clinical parameters {#Sec5}
-------------------

As described previously (van den Berg et al. [@CR32]), all participants were instructed to collect 24-h urine sample at the day prior to their visit to the outpatient clinic. First, blood pressure and heart rate were measured using a semi-automatic device (Dinamap^®^ 1846, Critikon, Tampa, FL, USA) every minute for the duration of 15 min, following a strict protocol (van den Berg et al. [@CR30], [@CR31]). An average of the last three values was taken as a final value. Body weight and height were measured and body mass index (BMI) was calculated as weight divided by height square (kg/m^2^), body surface area was calculated using the universally adopted formula of DuBois & DuBois (Dubois and Dubois [@CR9]). In the morning after an overnight fasting period, blood was drawn and subsequently venous blood gas analyses were performed photometrically. Electrolytes, phosphate, albumin, urea and creatinine in plasma and urine were measured using routine laboratory methods, which was also the case for serum cholesterol, HbA1c and hsCRP. Renal function was assessed by calculating the estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) equation (Levey Levey et al. [@CR19]). Serum calcium was corrected for hypoalbuminemia (\<40 g/L) using the following formula: corrected calcium = serum calcium (mmol/L) + 0.02 × \[40 − serum albumin (g/L)\]. Intact FGF-23 was measured using a commercially available ELISA kit (Kainos Laboratories, Inc., Tokyo, Japan) (Baia et al. [@CR3]). Information on participants' health status, medical history and medication use was extracted from patient records. Relevant transplant information was extracted from the UMCG renal transplant database. Smoking behavior was categorized to current, former or never smoked, using a self-report questionnaire.

Plasma ADMA {#Sec6}
-----------

Free ADMA was measured by a previously described fully validated GC--MS/MS method (Tsikas et al. [@CR29]). The analyses were performed on a ThermoQuest TSQ 7000 mass spectrometer (Finnigan MAT, San Jose, CA, USA). ADMA was quantified by selected-reaction monitoring (SRM) of the transitions *mlz* 634 → *mlz* 378 for endogenous ADMA, whereas for the internal standard *mlz* 637 → *mlz* 378 was used. The dwell time was 100 ms for each analyte and each transition. The basal plasma concentration of the QC samples was 380 nM for ADMA.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were performed using SPSS 22.0 for Windows (SPSS Corp. Chicago, IL, USA) and GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). Non-normally distributed parameters were presented as median \[interquartile range (IQR)\] and normally distributed variables were expressed as mean ± standard deviation (SD). A two-sided *P* value \<0.05 was considered statistically significant. Histograms and probability plots were displayed followed by the Kolmogorov--Smirnov test to test the distribution of all parameters. When skewed, parameters were normalized for analyses by logarithmic transformation \[high-sensitive C-reactive protein (CRP), triglycerides, albuminuria, FGF-23, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), parathyroid hormone (PTH)\]. The study population was subdivided into tertiles of ADMA to visualize potential associations of plasma ADMA with different parameters in RTR. To establish *P* values for differences in ADMA tertiles, an ANOVA was used for normally distributed continuous data, whereas the Kruskal--Wallis test was used for non-normally distributed data and the χ^2^-test for nominal data. To identify the independent determinants of ADMA, univariable and multivariable linear regression analyses were performed. Multivariable linear regression models were constructed using backward selection (*P*~out~ \> 0.05), which included all twenty-one variables that were significantly associated with ADMA in the univariable analysis. Tertiles of ADMA were tested for associations with all-cause mortality and death-censored graft failure by Kaplan--Meier analysis, including the log-rank test. For the Cox regression analyses, models were constructed with inclusion of the potential confounders of ADMA. These are the parameters that significantly associated with plasma ADMA in the multivariable analysis. We first performed crude Cox regression analyses (model 1) and analyses with adjustment for age and gender (model 2). In addition, eGFR was added (model 3), and we adjusted for the potential confounders of ADMA, which were identified in the multivariable regression analysis (donor age, serum PTH, NT-pro-BNP, use of calcium supplements) (model 4). In the final model, we included intact FGF-23, to test whether the association of ADMA with all-cause mortality was influenced by this parameter (model 5). The same models were used to test the association of plasma ADMA with graft failure. We explored a potential interaction by FGF-23 for the association between ADMA and mortality in the full Cox regression model by adding the interaction term ADMA × FGF-23.

Results {#Sec8}
=======

Patient characteristics according to tertiles of plasma ADMA {#Sec9}
------------------------------------------------------------

Plasma ADMA was normally distributed and had a mean value of 0.61 ± 0.12 µmol/L (Fig. [1](#Fig1){ref-type="fig"}). The patient cohort of 686 RTR had a mean age of 53.0 ± 12.7 years and 57 % were male. Baseline characteristics of the patient cohort per tertile of ADMA are displayed in Table [1](#Tab1){ref-type="table"}. Median time between renal transplantation and baseline measurement was 5.4 \[1.9--12.0\] years. RTR in the highest tertile of ADMA were older and more likely to be male compared to RTR in the other tertiles, whereas the other demographic parameters were similar among ADMA tertiles. With regard to transplant characteristics, RTR with the highest ADMA levels less often received their kidney from living donors, and their donors tended to be older.Fig. 1Histogram of plasma ADMA showing normal distribution curve in RTR. Plasma ADMA (0.61 ± 0.12 µmol/L) measured in 686 renal transplant recipients was normally distributedTable 1Baseline patient characteristics presented as tertiles of plasma ADMARenal transplant recipients tertiles of ADMAOverall (*N* = 686)Tertile 1 (*N* = 249)Tertile 2 (*N* = 213)Tertile 3 (*N* = 224)*P* valueADMA (µmol/L)0.61 ± 0.12≤0.560.57--0.65≥0.66\<0.001Demographics Age, years53 ± 1350 ± 1354 ± 1255 ± 13**\<0.001** Male gender390 (57)127 (51)125 (59)138 (62)**0.05** Current smoker, *n* (%)82 (13)29 (13)31 (15)22 (11)0.38 Current diabetes, *n* (%)165 (24)51 (21)51 (24)63 (28)0.15 BMI, kg/m^2^27 ± 527 ± 527 ± 527 ± 50.84 BSA, m^2^1.94 ± 0.221.94 ± 0.191.95 ± 0.221.94 ± 0.220.72 Systolic blood pressure, mmHg136 ± 17136 ± 16135 ± 18138 ± 150.26 Diastolic blood pressure, mmHg83 ± 1183 ± 1082 ± 1282 ± 110.44 Heart rate, bpm69 ± 1269 ± 1368 ± 1269 ± 110.61Renal transplantation Transplant vintage, years5.4 \[1.9--12.1\]5.2 \[2.2--10.8\]5.2 \[2.0--11.6\]6.1 \[1.6--14.0\]0.51 Living donor, *n* (%)229 (34)103 (42)70 (34)56 (26)**0.001** Pre-emptive KTx, *n* (%)112 (16)51 (21)33 (16)28 (13)0.06 HLA mismatches, *n*2 \[1--3\]2 \[1--3\]2 \[1--3\]2 \[1--3\]0.31 Age donor, years43 ± 1640 ± 1643 ± 1545 ± 15**0.009** Acute rejection, *n* (%)181 (26)65 (26)54 (26)62 (28)0.86Laboratory measurements Hemoglobin, mmol/L8.2 ± 1.18.3 ± 1.08.2 ± 1.18.1 ± 1.20.09 HbA1C, %6.0 ± 0.85.9 ± 0.86.0 ± 0.86.0 ± 0.90.59 eGFR, CKD-EPI (ml/min/1.73 m^2^)52.2 ± 20.257.9 ± 21.451.2 ± 18.446.9 ± 19.0**\<0.001** Corrected calcium mmol/L2.34 ± 0.152.33 ± 0.152.35 ± 0.142.35 ± 0.140.42 Phosphate, mmol/L0.97 ± 0.210.94 ± 0.210.96 ± 0.211.01 ± 0.21**0.002** Magnesium, mmol/L0.95 ± 0.120.95 ± 0.120.95 ± 0.130.96 ± 0.120.81 PTH, pmol/L8.9 \[5.9--14.7\]8.1 \[5.6--12.0\]8.7 \[6.2--15.4\]11.0 \[6.5--17.3\]**0.001** Venous pH7.37 ± 0.047.37 ± 0.047.37 ± 0.047.36 ± 0.04**0.009** Venous HCO~3~ ^−^, mmol/L24.6 ± 3.124.8 ± 2.924.8 ± 3.224.2 ± 3.20.07 hsCRP, mg/L1.6 \[0.7--4.5\]1.6 \[0.7--4.6\]1.8 \[0.6--5.0\]1.5 \[0.8--4.4\]0.91 Albumin, g/L43.0 ± 3.043.6 ± 2.842.9 ± 2.842.4 ± 3.2**\<0.001** Alkaline phosphatase, U/L67 \[54--83\]66 \[51--79\]67 \[56--82\]69 \[54--92\]0.12 FGF-23, pg/mL61 \[43--99\]54 \[39--82\]60 \[46--93\]75 \[53--126\]**\<0.001** Total cholesterol, mmol/L5.0 \[4.4--5.8\]5.1 \[4.4--5.8\]5.0 \[4.4--5.8\]5.1 \[4.2--5.9\]0.95 HDL cholesterol, mmol/L1.3 \[1.1--1.6\]1.4 \[1.1--1.7\]1.3 \[1.1--1.7\]1.3 \[1.0--1.5\]**0.002** LDL cholesterol, mmol/L2.9 \[2.3--3.5\]2.9 \[2.4--3.5\]2.9 \[2.2--3.5\]2.9 \[2.3--3.6\]0.83 Triglycerides, mmol/L1.68 \[1.25--2.30\]1.63 \[1.13--2.23\]1.73 \[1.29--2.43\]1.69 \[1.28--2.3\]0.17 NT-pro-BNP, ng/L252 \[108--634150 \[76--405\]229 \[109--565\]396 \[185--1086\]**\<0.001** Albuminuria, mg/24 h40 \[11--177\]29 \[8--154\]28 \[10--103\]83 \[13--300\]**0.001**Medication Anti-hypertensives, *n* (%)606 (88)212 (85)190 (89)204 (91)0.12 Statins, *n* (%)361 (53)132 (53)105 (50)361 (53)0.45 Calcium supplements, *n* (%)147 (21)46 (19)46 (22)55 (25)0.27 Vitamin D supplements168 (25)63 (25)44 (21)61 (27)0.26 Vitamin K antagonists77 (11)19 (8)22 (10)36 (16)**0.01** Prednisone, mg/d10 \[7.5--10\]10 \[7.5--10\]10 \[7.5--10\]10 \[7.5--10\]0.19 Calcineurin inhibitors391 (57)120 (48)134 (63)137 (61)**0.002** Proliferation inhibitor572 (83)222 (89)171 (80)179 (80)**0.009** Sirolimus13 (2)5 (2)7 (3)1 (1)0.10Data are presented as mean ± SD, number (percentage) or median (IQR). Statistical analysis was performed using ANOVA, Kruskal--Wallis or χ^2^-test when appropriate. Bold indicates statistical significance (*P* \< 0.05)*ADMA* asymmetrical dimethylarginine, *BSA* body surface area, *eGFR* estimated glomerular filtration rate, *HbA1c* glycated hemoglobin, *HCO* ~*3*~^*−*^ bicarbonate, *HDL* high-density lipoprotein, *HLA* human leukocyte antigen, *hsCRP* high-sensitivity C-reactive protein, *KTx* kidney transplantation, *LDL* low-density lipoprotein, *PTH* parathyroid hormone

Estimated GFR was lower and urinary protein excretion higher in RTR with the highest ADMA. Serum phosphate, PTH and levels of NT-pro-BNP were significantly increased in RTR in the highest ADMA tertile, whereas serum albumin levels, HDL cholesterol and venous pH were significantly lower when compared to RTR with the lowest ADMA level. RTR with the highest levels of ADMA also had the highest levels of intact FGF-23. With regard to medication use, RTR with the highest plasma ADMA more often used vitamin K antagonist and calcineurin inhibitors when compared to the lowest ADMA tertile, while the use of proliferation inhibitors was less. Table [2](#Tab2){ref-type="table"} provides an overview of associations of ADMA levels with different parameters in univariable and multivariable regression analyses. The strongest associations with plasma ADMA in the multivariable analyses were male gender, donor age, PTH, NT-pro-BNP and use of calcium supplements. When adding NT-pro-BNP to the linear regression analysis with backward selection, eGFR lost its significant association with ADMA.Table 2Associations of plasma ADMA with clinical parameters in RTRPlasma ADMAUnivariableMultivariableSt. Beta*P* valueSt. Beta*P* valueDemographics Age, years0.123**\<0.001** Male gender0.082**0.03**0.133**0.001** Current smoker−0.0110.78 Current diabetes0.0710.06 BMI, kg/m^2^−0.0460.23 BSA, m^2^−0.0460.23 SBP, mmHg0.0260.50 DBP, mmHg−0.0390.31 Heart rate, bpm0.0060.87Renal transplantation Transplant vintage, years0.040.30 Living donor−0.127**0.001** Pre-emptive KTx−0.098**0.01** HLA mismatches−0.0220.57 Age donor, years0.110**0.005**0.094**0.02** Acute rejection0.0160.67Laboratory measurements Hemoglobin, mmol/L−0.082**0.03** HbA1C, %0.0100.80 eGFR, CKD-EPI (ml/min/1.73 m^2^)−0.209**\<0.001** Corrected calcium mmol/L0.0590.13 Phosphate, mmol/L0.107**0.005** Magnesium, mmol/L0.0140.72 PTH, pmol/L0.119**0.002**0.104**0.01** Venous pH−0.123**0.002** Venous HCO~3~, mmol/L−0.108**0.006** hsCRP, mg/L−0.0160.68 Albumin, g/L−0.160**\<0.001** Alkaline phosphatase, U/L0.0580.13 FGF-23, pg/mL0.185**\<0.001** Total cholesterol, mmol/L−0.0520.18 HDL cholesterol, mmol/L−0.139**\<0.001** LDL cholesterol, mmol/L−0.0210.58 Triglycerides, mmol/L0.0360.34 NT-pro-BNP, ng/L0.271**\<0.001**0.265**\<0.001** Albuminuria, mg/24 h0.115**0.003**Medication Anti-hypertensives0.081**0.03** Statins0.0320.40 Calcium supplements0.085**0.03**0.088**0.03** Vitamin D supplements0.0290.44 Vitamin K antagonists0.125**0.001** Prednisone, mg/d0.0550.15 Calcineurin inhibitors0.092**0.02** Proliferation inhibitor−0.101**0.008** Sirolimus−0.0650.10Regression coefficients are given as standardized betas, i.e., change of cardiovascular parameter in SD, per SD increase of plasma ADMA level*P* values less than 0.05 are in bold*ADMA* asymmetrical dimethylarginine, *BMI* body mass index, *BSA* body surface area, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FGF-23* fibroblast growth factor 23, *hsCRP* high-sensitive C-Reactive Protein, *HDL cholesterol* high-density lipoprotein, *LDL* low-density lipoprotein, *NT-pro-BNP* N-terminal pro-Brain Natriuretic peptide, PTH parathyroid hormone, *HbA1c* glycated hemoglobin, *eGFR* estimated glomerular filtration rate

ADMA is associated with increased all-cause mortality in RTR, independent of FGF-23 {#Sec10}
-----------------------------------------------------------------------------------

Of the 686 RTR in our cohort, 79 (12 %) died within a median follow-up period of 3.1 \[2.7--3.9\] years. In the highest tertile of ADMA, 44 out of 224 (20 %) died, while this was 22 out of 213 (10 %) in the middle tertile and 13 out of 249 (5 %) in the tertile with the lowest ADMA levels (log-rank test *P* \< 0.001, Fig. [2](#Fig2){ref-type="fig"}). In addition, we performed Cox regression analyses with potential confounders of plasma ADMA that were identified in the multivariable regression analyses (Table [3](#Tab3){ref-type="table"}). The crude Cox regression analysis (model 1) showed that plasma ADMA is associated with increased mortality risk \[HR 1.52 (95 % CI 1.26--1.83), *P* \< 0.001 per SD increase\]. After adjusting for age and gender \[model 2; HR 1.52 (1.22--1.88), *P* \< 0.001\], for eGFR \[model 3; HR 1.43 (1.15--1.78), *P* = 0.001\] and other potential confounders in multivariate regression analysis \[model 4; HR 1.34 (1.07--1.68), *P* = 0.01\], plasma ADMA remained significantly associated with increased mortality risk in RTR. In the final model, we also added FGF-23, however, this did not affect the association of plasma ADMA with all-cause mortality \[model 5; HR 1.34 (1.07--1.68), *P* = 0.01\]. We found no significant interaction by FGF-23 for the association between ADMA and mortality (*P* = 0.23).Fig. 2Kaplan--Meier plot of the association of ADMA with all-cause mortality in RTR. Higher plasma levels of ADMA are associated with significantly increased all-cause mortality in renal transplant recipients. Kaplan--Meier curve displayed for all-cause mortality, with log-rank test *P* value \<0.001Table 3Associations of plasma ADMA with all-cause mortality in RTRPlasma ADMA (continuous)HR (95 % CI) per SD*P* valueModel 11.52 (1.26--1.83)**\<0.001**Model 21.52 (1.22--1.88)**\<0.001**Model 31.43 (1.15--1.78)**0.001**Model 41.34 (1.07--1.68)**0.01**Model 51.34 (1.07--1.68)**0.01**Model 1: crude, Model 2: adjusted for age, gender, Model 3: as model 2, additionally adjusted for Egfr, Model 4: as model 3, additionally adjusted for donor age, PTH, NT-pro-BNP, use of calcium supplements, Model 5: as model 4, additionally adjusted for FGF-23*P* values less than 0.05 are in bold*ADMA* asymmetric dimethylarginine, *CI* confidence interval, *FGF-23* fibroblast growth factor 23, *HR* hazard ratio, *NT-pro-BNP* N-terminal pro-hormone of brain natriuretic peptide, *PTH* parathyroid hormone, *SD* standard deviation

ADMA is associated with graft failure in RTR; lost significance after adding renal function {#Sec11}
-------------------------------------------------------------------------------------------

In our cohort, 45 (7 %) RTR developed graft failure in a median follow-up period of 3.1 \[2.7--3.9\] years. In the highest tertile of ADMA, 19 out of 224 (9 %) developed graft failure, while this was 16 out of 213 (8 %) and 10 out of 249 (4 %) in the middle and lowest tertile of ADMA, respectively (log-rank test *P* = 0.10). In the crude Cox regression analysis, plasma ADMA was significantly associated with graft failure \[HR 1.41 (1.08--1.83), *P* = 0.01\] (Table [4](#Tab4){ref-type="table"}). Upon adjustment for age and gender, plasma ADMA remained significantly associated with graft failure \[HR 1.42 (1.11--1.82), *P* = 0.01\]. However, when adding eGFR, the significant association of ADMA with graft failure was lost (HR 1.26 (0.95--1.68), *P* = 0.11\].Table 4Associations of plasma ADMA with graft failure in RTRPlasma ADMA (continuous)HR (95 % CI) per SD*P* valueModel 11.41 (1.08--1.83)**0.01**Model 21.42 (1.11--1.82)**0.01**Model 31.26 (0.95--1.68)0.11Model 41.11 (0.81--1.51)0.52Model 51.10 (0.80--1.49)0.57Model 1: crude, Model 2: adjusted for age, gender, Model 3: as model 2, additionally adjusted for eGFR, Model 4: as model 3, additionally adjusted for donor age, PTH, NT-pro-BNP, use of calcium supplements, Model 5: as model 4, additionally adjusted for FGF-23*P* values less than 0.05 are in bold*ADMA* asymmetric dimethylarginine, *CI* confidence interval, *FGF-23* fibroblast growth factor 23, *HR* hazard ratio, *NT-pro-BNP* N-terminal pro-hormone of brain natriuretic peptide, *PTH* parathyroid hormone, *SD* standard deviation

Discussion {#Sec12}
==========

Plasma ADMA is associated with increased risk of all-cause mortality in stable renal transplant recipients. This association was solid and independent of various potential confounders. These results are in line with the current conception of ADMA as a serious risk factor for cardiovascular disease, the primary cause of death in RTR.

ADMA is an endogenous inhibitor of NO synthase that has the potential to negatively affect endothelial function, blood pressure and vascular remodeling (Leiper [@CR18]) via reduction of the production of NO. High levels of ADMA are acknowledged as a risk factor for cardiovascular disease in CKD patients (Abedini et al. [@CR1]; Lu et al. [@CR20]; Ravani et al. [@CR25]) and associate with increased mortality in patients undergoing coronary angiography (Meinitzer et al. [@CR22]). Where others have described ADMA and NT-pro-BNP as independent risk markers (Duckelmann et al. [@CR10]), the results of the present study demonstrate a strong association between plasma ADMA and NT-pro-BNP in RTR. Despite this strong association, our results show that ADMA still is an independent risk factor associated with mortality in RTR. Since ADMA significantly inhibits NOS and reduces NO production in vitro in endothelial cells and isolated human blood vessels (Faraci et al. [@CR11]) and ADMA administration to healthy rats (Gardiner et al. [@CR13]) as well as healthy humans (Kielstein et al. [@CR17]) induced increased blood pressure, increased renal vasculature resistance and decreased cardiac output, one might hypothesize that high levels of ADMA can cause left ventricular wall stress with increased NT-pro-BNP levels. The link between endothelial dysfunction and vascular hypertrophy has already been demonstrated in end-stage renal disease patients (Zoccali et al. [@CR36]). Furthermore, in patients with CKD, plasma ADMA was addressed as an independent risk factor for cardiac hypertrophy and associated with cardiovascular events (Shi et al. [@CR26]).

We found a borderline significant inverse relationship between ADMA and renal function in RTR. This association was also demonstrated in CKD patients (Ravani et al. [@CR25]; Fliser et al. [@CR12]; Tripepi et al. [@CR28]), whereby ADMA predicted the incidence rate of renal events (decrease in eGFR of \>30 %, dialysis, or kidney transplantation (Tripepi et al. [@CR28]). The association of ADMA with renal function decline and renal events might be explained by its inhibitory effects on NO production, which in turn leads to deteriorated renal function and renal fibrosis (Mihout et al. [@CR23]). However, in the present study we demonstrated that, by the addition of NT-pro-BNP to the multivariate model, eGFR lost its significant association with ADMA. Apparently, NT-pro-BNP is an even stronger determinant of ADMA than renal function. This might be related to the fact that they are both involved in cardiovascular dynamics.

Furthermore, others found a link between levels of ADMA and graft failure (Abedini et al. [@CR1]). In the present study, we confirmed this association; however, significance was lost after adjustment for renal function. This can be explained by the fact that renal function by itself is a strong predictor for graft failure (Hariharan et al. [@CR15]) and might also be a consequence of the low number of events in our cohort. Thereby, in the present study, the way of classifying graft failure differed from Abedini et al., since we only took into account the RTR that returned to dialysis or had to undergo re-transplantation, whereas they also included doubling of serum creatinine into this category (Abedini et al. [@CR1]). Our study is in line with the work of Abedini et al. who, in a cohort of renal transplant recipients with slightly different patients' characteristics, also found a significant association between ADMA and mortality. However, our study adds that ADMA is significantly associated with NT-pro-BNP, but is independently associated with all-cause mortality. This latter also holds true for ADMA and FGF-23.

A potential shared causal pathway of FGF-23 and ADMA in the development of endothelial dysfunction was recently proposed (Yilmaz et al. [@CR35]). In line with this, FGF-23 was previously reported to modify the association between ADMA and renal function loss in CKD patients (Tripepi et al. [@CR28]). In the present study, we examined whether the association of plasma ADMA with mortality is mediated by FGF-23, however, from our results we conclude that the association between ADMA and all-cause mortality is independent of plasma intact FGF-23 in RTR. We also found no evidence of interaction by FGF-23 for the association between ADMA and mortality in our cohort.

One of the strengths of our study is the large sample size of well-defined, stable RTR. Extensive data collection, including data from 24-h urine samples allowed for adjustment for many confounders. Despite this, our study is strictly an observational epidemiological study. Causality is, therefore, hard to prove. Since little is known about how ADMA affects cardiovascular parameters in this cohort, other factors might underlie the observed associations. Furthermore, our study population consisted predominantly of Caucasian people, which calls prudence to extrapolation of our results to populations of other ethnicities. Furthermore, we need to keep in mind that circulating levels of ADMA in some cases reflect the intracellular concentrations (Davids et al. [@CR8]), however, they are not necessarily in equilibrium with each other (Davids and Teerlink [@CR7]).

In conclusion, high levels of plasma ADMA are associated with increased mortality in RTR. Since it is not yet clear whether ADMA is rather a progression marker of disease, a novel risk factor of disease or both, additional studies to sort out these issues are warranted. Currently, therapies to reduce ADMA levels are being tested for their efficacy, as well as to evaluate their therapeutic effect in diseases characterized by endothelial dysfunction.
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:   High-density lipoprotein

HLA

:   Human leukocyte antigen

HR

:   Hazard risk

IQR

:   Interquartile range

KTx

:   Kidney transplantation

LDL

:   Low-density lipoprotein

eNOS

:   Endothelial nitric oxide synthase

NT-pro-BNP

:   N-terminal pro-brain natriuretic peptide

PTH

:   Parathyroid hormone

QC

:   Quality control

RTR

:   Renal transplant recipients

SBP

:   Systolic blood pressure
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